Wedbush Reaffirms Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO)

Posted by Geri Gentry on Aug 14th, 2026

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research note issued on Friday,Benzinga reports. They currently have a $45.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 54.11% from the company’s current price.

A number of other analysts have also commented on ZBIO. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Finally, Morgan Stanley boosted their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.29.

View Our Latest Research Report on Zenas BioPharma

Zenas BioPharma Trading Down 6.7%

Shares of ZBIO stock opened at $29.20 on Friday. Zenas BioPharma has a 52-week low of $13.50 and a 52-week high of $44.60. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The company has a 50-day simple moving average of $26.71 and a two-hundred day simple moving average of $23.34. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -3.45 and a beta of -1.03.

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The business had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. Research analysts anticipate that Zenas BioPharma will post -4.47 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 60,000 shares of Zenas BioPharma stock in a transaction dated Monday, May 18th. The stock was purchased at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the completion of the purchase, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 22.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Zenas BioPharma by 71.3% during the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after acquiring an additional 8,207 shares in the last quarter. Sei Investments Co. bought a new position in shares of Zenas BioPharma in the second quarter worth $118,000. Bank of America Corp DE grew its position in shares of Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after purchasing an additional 3,412 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after purchasing an additional 170,546 shares in the last quarter.

About Zenas BioPharma

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.